Dr. Reddy’s to Acquire Select Anti-Allergy Brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan
HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as
Sinovac COVID-19 vaccine collaboration with Butantan approved by Brazilian regulator for Phase III Trial
Sinovac Biotech’s partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines, has reached a milestone as it moved one step further to our commitment to developing vaccines for global use after getting the approval for Phase 3 trial from Brazilian National Regulatory Agency, Anvisa.
Sinovac Biotech, a provider of biopharmaceutical producs in China, has reported sales for the first quarter of 2020 at $15.4 million, a decrease of 57.9% from $36.6 million in the prior year period, with a loss attributed to common shareholders of $7.4 million, in the same period.
TAIZHOU, China–(BUSINESS WIRE)–#Avigan–Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy
HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form
Mylan and Lupin Limited have received from the European Commission (EC) marketing authorization for Nepexto, a biosimilar to Enbrel, for all indications of the reference product.
FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced the U.S. Food and Drug Administration
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
Validation of Type II Variation will allow Takeda to commence launches in Europe later this year The pre-filled syringe presentation
Seal of quality for outstanding corporate management Analysis of the areas of strategy, innovation, corporate culture and finance Comprehensive three-stage
Advantech Capital and Vivo Capital have invested $15 million in Sinovac Research and Development Co., Ltd. (“Sinovac R&D”), a wholly owned subsidiary of Sinovac, to further the development of an inactivated vaccine against COVID-19 named CoronaVac.